Harry de Koning, Professor of Public Health & Screening Evaluation, Erasmus Medical Center, Rotterdam, The Netherlands

Harry de Koning

Professor de Koning MD, PhD worked as an assistant professor in the department of public health of Erasmus University in Rotterdam from 1987 to 1999. He became an associate professor in 1999, and in 2008 he was appointed Professor of Public Health and Screening Evaluation. His major scientific contributions are in the areas of (1) design, management, and evaluation of large-scale multidisciplinary population-based randomised controlled trials to establish the efficacy of screening; (2) evaluation of active international screening programmes and tests to establish their effectiveness; and (3) guidance of public health policies through use of predictions of favourable and unfavourable effects of and the cost of screening, based on micro-simulation modelling of the natural history of disease and cost-effectiveness and cost-utility analyses. Professor de Koning designed and is principal investigator of the NELSON lung cancer screening trial. This trial was the first to show that lung nodules detected by CT scanning can be managed safely with conservative follow-up schedules when including volume-doubling times in the algorithm. He has 392 peer-reviewed international publications and an H-index of 60 in Scopus. His research focuses on quantifying the health benefits, unfavourable side-effects, impact on quality of life, and cost consequences of introducing screening programmes, resulting in recommendations and policy decision on whether and how to introduce new screening programmes. The strength of the research group, which currently comprises 35 members, lies in its multidisciplinary focus.

« Go Back

Supporting Publications
Organised by
  • Elsevier
  • TLP
  • TLN
  • Autoimmune Encephalitis (AE) Alliance
  • Encephalitis Society
  • Treating Autism
  • Encephalitis Society
  • Epitech
  • Treating Autism